AU2002348394A1 - Tyrosine kinase inhibitors - Google Patents

Tyrosine kinase inhibitors

Info

Publication number
AU2002348394A1
AU2002348394A1 AU2002348394A AU2002348394A AU2002348394A1 AU 2002348394 A1 AU2002348394 A1 AU 2002348394A1 AU 2002348394 A AU2002348394 A AU 2002348394A AU 2002348394 A AU2002348394 A AU 2002348394A AU 2002348394 A1 AU2002348394 A1 AU 2002348394A1
Authority
AU
Australia
Prior art keywords
tyrosine kinase
kinase inhibitors
inhibitors
tyrosine
kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002348394A
Inventor
Ian M. Bell
Craig Lindsley
B. Wesley Trotter
C. Blair Zartman
Zhijian Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU2002348394A1 publication Critical patent/AU2002348394A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
AU2002348394A 2001-10-25 2002-10-21 Tyrosine kinase inhibitors Abandoned AU2002348394A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34311901P 2001-10-25 2001-10-25
US60/343,119 2001-10-25
PCT/US2002/033920 WO2003035615A2 (en) 2001-10-25 2002-10-21 Tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
AU2002348394A1 true AU2002348394A1 (en) 2003-05-06

Family

ID=23344789

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002348394A Abandoned AU2002348394A1 (en) 2001-10-25 2002-10-21 Tyrosine kinase inhibitors

Country Status (2)

Country Link
AU (1) AU2002348394A1 (en)
WO (1) WO2003035615A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006528629A (en) * 2003-07-24 2006-12-21 メルク　エンド　カムパニー　インコーポレーテッド Tyrosine kinase inhibitor
US7538231B2 (en) 2003-07-24 2009-05-26 Merck & Co, Inc. Tyrosine kinase inhibitors
EP1747206A1 (en) 2004-04-29 2007-01-31 Abbott Laboratories Amino-tetrazoles analogues and methods of use
US7453002B2 (en) * 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
WO2006039215A2 (en) * 2004-09-30 2006-04-13 Janssen Pharmaceutica N.V. Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms)
WO2007035744A1 (en) 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
JP2012519170A (en) 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー INSITU method for monitoring EMT status of tumor cells in vivo
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401614A1 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
CA2783665A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20110275644A1 (en) 2010-03-03 2011-11-10 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2544672A1 (en) 2010-03-09 2013-01-16 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
EP2702173A1 (en) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
AU2014223548A1 (en) 2013-02-26 2015-10-15 Triact Therapeutics, Inc. Cancer therapy
EA029661B1 (en) 2013-09-06 2018-04-30 Ауриген Дискавери Текнолоджиз Лимитед 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
EP3044593A4 (en) 2013-09-09 2017-05-17 Triact Therapeutics, Inc. Cancer therapy
US11161823B2 (en) 2019-03-11 2021-11-02 National Guard Health Affairs Anticancer 1,3-dioxane-4,6-dione derivatives and method of combinatorial synthesis thereof

Also Published As

Publication number Publication date
WO2003035615A3 (en) 2004-03-18
WO2003035615A2 (en) 2003-05-01

Similar Documents

Publication Publication Date Title
AU2002361577A1 (en) Tyrosine kinase inhibitors
AU2002334355A1 (en) Protein tyrosine kinase inhibitors
AU2003299651A1 (en) Tyrosine kinase inhibitors
EP1381598A4 (en) Novel tyrosine kinase inhibitors
AU2001237041A1 (en) Kinase inhibitors
AU2003298942A1 (en) Tyrosine kinase inhibitors
AU2003282891A1 (en) Novel tyrosine kinases inhibitors
AU2000240570A1 (en) Pyrrolopyrimidines as tyrosine kinase inhibitors
AU2002305260A1 (en) Pyrazole derived kinase inhibitors
AU2437900A (en) Piperidinylquinolines as protein tyrosine kinase inhibitors
AU2002348394A1 (en) Tyrosine kinase inhibitors
AU2003275282A1 (en) Novel tyrosine kinase inhibitors
EP1534268A4 (en) Tyrosine kinase inhibitors
AU2002357193A1 (en) Thienopyrimidine compounds as protein tyrosine kinase inhibitors
AU2002348020A1 (en) Tyrosine kinase inhibitors
EP1259236A4 (en) Tyrosine kinase inhibitors
AU2002348393A1 (en) Tyrosine kinase inhibitors
AU2002323406A1 (en) Tyrosine kinase inhibitors
EP1496897A4 (en) Tyrosine kinase inhibitors
AU2002327534A1 (en) Tyrosine kinase inhibitors
AU2001241917A1 (en) Myt1 kinase inhibitors
AU2002253350A1 (en) 4-aminosulfonylquinazolines and -quinolines as tyrosine kinase inhibitors
AU2002327619A1 (en) Tyrosine kinase inhibitors
AU2002322568A1 (en) Tyrosine kinase inhibitors
AU2002337972A1 (en) Tyrosine kinase inhibitors

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase